Key result
Cardiac CaMKII inhibition lowers ventricular rate during AF and tachycardia by slowing AVN conduction in mice.
Why the study?
The effectiveness of CaMKII inhibition on tachycardia and its underlying mechanism in affecting AVN electrophysiology remained unclear.
Does CaMKII inhibition reduce ventricular rates during atrial fibrillation and tachycardia in a mouse model?
Does CaMKII inhibition reduce ventricular rates during atrial fibrillation and tachycardia in a mouse model?
CaMKII inhibition effectively decreases ventricular rates during atrial fibrillation and tachycardia by slowing AVN conduction through the suppression of intracellular Ca2+ overload.
No takes yet. Share an insight, caveat, or question.
CaMKII inhibition may aid rate control in AF models; hypothesis-generating and leaves open translation to human therapy.
Chen et al. (2024) studied Atrial fibrillation and tachycardia. Cardiac CaMKII inhibition vs. Wild-type mice was evaluated on Ventricular rate during atrial fibrillation and isoproterenol-induced tachycardia. Cardiac CaMKII inhibition decreased the ventricular rate during atrial fibrillation and isoproterenol-induced tachycardia by slowing AVN conduction compared to wild-type mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: